Patrick A. BaeuerlePhD
Patrick A. Baeuerle, Ph.D., joined MPM in 2015. Patrick is responsible for the development of BiTE antibody Blincyto (blinatumomab; AMG 103) which was approved within three months by the US FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the development of the BiTE technology, the industry- leading T-cell engaging antibody platform.
Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.
Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.